Members |
targetComponentId |
Curettage of organ NOC NOS |
Scraping done with a curette |
Curettage of organ NOC OS |
Scraping done with a curette |
Curettage af graviditetsprodukter fra uterus, ikke klassificeret andetsteds |
Dilation of cervix uteri and curettage of products of conception from uterus |
Curettage products conception: [uterus NEC (& retained)] or [termination NEC] |
Dilation of cervix uteri and curettage of products of conception from uterus |
Curling esophagus |
Diffuse spasm of esophagus |
kurvatur af rygsøjlen, ikke nærmere specificeret |
Curvature of spine |
Curvature of spine NOS |
Curvature of spine |
Curvature of stomach |
Stomach part |
kutan CD30-positiv lymfoproliferativ sygdom |
Primary cutaneous CD30+ large T-cell lymphoma |
kutant T-celle-lymfom |
Cutaneous T-cell lymphoma |
Kutan anafylaksi |
Localised anaphylaxis |
Kutan eruption |
Eruption |
Cutaneous larva migrans NOS |
Cutaneous larva migrans |
Cutaneous larva migrans NOS |
Cutaneous larva migrans |
cyanocobalamin 25 µg næsespray |
Product containing only cyanocobalamin in nasal dose form (medicinal product form) |
cyanocobalamin 500 µg næsespray |
Cyanocobalamin 500 microgram/actuation nasal spray |
cyanocobalamin[57Co] 370kBq/ml oral opløsning |
Cyanocobalamin (57-Co) only product in oral dose form |
cyanocobalamin[58Co] 370 kBq/ml oral opløsning |
Product containing only cyanocobalamin (58-Co) in oral dose form (medicinal product form) |
CyberKnife |
Robotic radiation delivery system |
cyklisk ødem |
Edema |
cykloanæmisering |
Destruction of ciliary body |
Cyclopentolate hydrochloride + phenylephrine hydrochloride |
Product containing cyclopentolate and phenylephrine (medicinal product) |
Cyclopentolate hydrochloride 0.5% conventional release eye drops |
Cyclopentolate hydrochloride 5 mg/mL eye solution |
cyclopentolathydrochlorid 0,5 % øjendråber til engangsbrug |
Cyclopentolate hydrochloride 5 mg/mL eye solution |
Cyclopentolate hydrochloride 1% conventional release eye drops |
Cyclopentolate hydrochloride 10 mg/mL eye solution |
cyclopentolathydrochlorid 1 % øjendråber til engangsbrug |
Cyclopentolate hydrochloride 10 mg/mL eye solution |
cyclopentolathydrochlorid 2 % øjendråber |
Cyclopentolate hydrochloride 20 mg/mL eye solution |
Cyclophosphamide 1g/vial injection |
Cyclophosphamide 1 g powder for solution for injection vial |
Cyclophosphamide 1g/vial powder for injection |
Cyclophosphamide 1 g powder for solution for injection vial |
Cyclophosphamide 200mg/vial injection |
Cyclophosphamide 200 mg powder for solution for injection vial |
cyclophosphamid 200 mg/hætteglas pulver til injektionsvæske |
Cyclophosphamide 200 mg powder for solution for injection vial |
cyclophosphamid 2 g/hætteglas injektionsvæske |
Product containing precisely cyclophosphamide 2 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Cyclophosphamide 500mg/vial injection |
Cyclophosphamide 500 mg powder for solution for injection vial |
Cyclophosphamide 500mg/vial powder for injection |
Cyclophosphamide 500 mg powder for solution for injection vial |
Cyclopropane [no agents] |
Cyclopropane |
ciclosporin 50 mg/1 ml olieholdigt koncentrat til infusionsvæske |
Product containing precisely ciclosporin 50 milligram/1 milliliter conventional release solution for injection (clinical drug) |
ciclosporin 100 mg/5 ml opløsning |
Product containing only ciclosporin (medicinal product) |
ciclosporin 100 mg/ml opløsning |
Ciclosporin 100 mg/mL oral solution |
Cyclosporine 50mg gel |
Ciclosporin 50 mg oral capsule |
ciclosporin 0,05 % øjenemulsion |
Product containing precisely ciclosporin 500 microgram/1 milliliter conventional release eye suspension (clinical drug) |
Cylindrical cell papilloma uncertain whether benign or malignant |
Oncocytic Schneiderian papilloma of uncertain behavior (morphologic abnormality) |
Cylindrocarpon tonkinense |
Neocosmospora lichenicola (organism) |
cyproheptadinhydrochlorid 2 mg/5 ml syrup til oral anvendelse |
Product containing precisely cyproheptadine hydrochloride 400 microgram/1 milliliter conventional release oral solution (clinical drug) |
Cyriax's syndrome |
Tietze's disease |
Cyst of Bartholin's gland |
Cyst of Bartholin's gland duct |
Cyst of bursa |
Bursal cyst (morphologic abnormality) |
testiscyste |
Cyst of testis (disorder) |
cysteamin 0,1 % øjendråber |
Product containing precisely mercaptamine 1 milligram/1 milliliter conventional release eye solution (clinical drug) |
Cysteine carboxypeptidase |
Cysteine carboxypeptidase |
Cysteine proteinase |
Cysteine proteinase |
Cystic disease |
Fibrocystic change |
Cystic fibrosis with other manifestations |
Cystic fibrosis |
Cystic fibrosis with other manifestations |
Cystic fibrosis |
cystocele med indvirkning på obstetrisk behandling og pleje |
Cystocele in pregnancy, childbirth and the puerperium |
Cystography |
Fluoroscopic cystography (procedure) |
Cystografi, ikke nærmere specificeret |
Cystography |
Cystography NOS |
Cystography |
Cystoskopisk eksstirpation af morfologisk forandring i blæren, ikke nærmere specificeret |
Cystoscopy and destruction of lesion of urinary bladder |
Cystoscopy: [diagnostic NOS] or [unspecified check] |
Transurethral cystoscopy (procedure) |
Cytarabine 100mg injection (pdr for recon)+diluent |
Product containing only cytarabine in parenteral dose form (medicinal product form) |
cytarabin 100 mg pulver til injektionsvæske, opløsning, hætteglas |
Product containing only cytarabine in parenteral dose form (medicinal product form) |
Cytarabine 1g injection (pdr for recon)+diluent |
Product containing only cytarabine in parenteral dose form (medicinal product form) |
cytarabin 1 g pulver til injektionsvæske, opløsning, hætteglas |
Product containing only cytarabine in parenteral dose form (medicinal product form) |
cytochrom P450 CYP2C9-enzymmangel |
Cytochrome P450 family 2 subfamily C member 9 poor metabolizer (finding) |
cytochrom P450 CYP2D6-enzymmangel |
Cytochrome P450 family 2 subfamily D member 6 poor metabolizer (finding) |
Cytochrome-b reductase deficiency |
Dihydrolipoamide dehydrogenase deficiency |
Cytology of organ NOC |
Cytologic test (procedure) |
Cytology of organ NOC NOS |
Cytologic test (procedure) |
cytopatologisk procedure eller service |
Cytopathology procedure |
Cytophaga uliginosa |
Zobellia uliginosa (organism) |
cytostatisk middel |
Cytotoxic |
Cytotoxic agent |
Cytotoxic |
Cytotoxic drug therapy NOS |
The treatment of disease using chemical agents or drugs that are selectively toxic to the causative agent of the disease, such as a virus, bacterium, or other microorganism. |
Cytotoxic drug therapy NOS |
The treatment of disease using chemical agents or drugs that are selectively toxic to the causative agent of the disease, such as a virus, bacterium, or other microorganism. |
Cytotoxic injection NOS |
Administration using positive pressure and a needle or other equipment to drive a substance into the body. |
Cytotoxic injection NOS |
Administration using positive pressure and a needle or other equipment to drive a substance into the body. |
DF-1 Group |
Capnocytophaga ochracea |
DHSS medical examination NOS |
Specialized medical examination |
DS1500 attendance allowance NOS |
Attendance allowance medical (procedure) |
undersøgelse ifm. attendance allowance-ordningen, DS1500 |
Attendance allowance medical (procedure) |
DS4 attend allowance exam NOS |
Attendance allowance medical (procedure) |
Dacarbazine 200mg/vial injection |
Product containing precisely dacarbazine (as dacarbazine citrate) 200 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Daclizumab 25mg/5 mL solution |
Daclizumab only product in parenteral dose form |
Daclizumab 25mg/5mL conventional release solution for injection |
Daclizumab only product in parenteral dose form |
daclizumab 25 mg/5 ml koncentrat til infusionsvæske |
Daclizumab only product in parenteral dose form |
Dacron |
Polyethylene terephthalate (substance) |
dakryocystorinostomi og indsættelse af tube, uanset yderligere specifikation |
Dacryocystorhinostomy and insertion of tube |
Dactylaria constricta var constricta |
Ochroconis constricta |
Daily |
Daily |
Daily life psychotherapy NOS |
Daily life psychotherapy |
Daily life psychotherapy NOS |
Daily life psychotherapy |
Daily life rehabilitation NOS |
Daily life rehabilitation |
Daily life rehabilitation NOS |
Daily life rehabilitation |
Daktarin oral gel 15g |
Product manufactured as oromucosal dose form (product) |
Skade på bækkenorgan eller -væv , ikke nærmere specificeret, efter mislykket graviditet |
Damage to pelvic organs or tissues following abortive pregnancy |
Damage to pelvic organ or tissues NOS following abortive pregnancy |
Damage to pelvic organs or tissues following abortive pregnancy |
Damaliscus dorcas |
Damaliscus pygargus (organism) |
Damp environment |
Damp environment |
Danaparoid sodium |
Product containing danaparoid (medicinal product) |
bivirkning af danaparoidnatrium |
Adverse reaction to danaparoid (disorder) |
allergi over for danaparoidnatrium |
Allergy to danaparoid (finding) |